A5010154254- Malaria Research and Control
- Mosquito-borne diseases and control
- Computational Drug Discovery Methods
- Global Maternal and Child Health
- Parasites and Host Interactions
- Viral Infections and Outbreaks Research
- HIV/AIDS drug development and treatment
- Child Nutrition and Water Access
- SARS-CoV-2 detection and testing
- SARS-CoV-2 and COVID-19 Research
- Vibrio bacteria research studies
- Drug-Induced Hepatotoxicity and Protection
- Pharmaceutical Quality and Counterfeiting
- Pharmacological Effects and Toxicity Studies
- COVID-19 epidemiological studies
- Epilepsy research and treatment
- Diverse Scientific Research Studies
- Genetics, Bioinformatics, and Biomedical Research
- Biosensors and Analytical Detection
- Research on Leishmaniasis Studies
Ifakara Health Institute
2016-2024
Muhimbili University of Health and Allied Sciences
2024
National Institute for Medical Research
2024
Catholic University of Health and Allied Sciences
2023-2024
Bugando Medical Centre
2023-2024
University of Gothenburg
2024
World Health Organization - Pakistan
2024
U.S. President's Malaria Initiative
2024
National Office for Sanitation of Senegal
2024
Artemisinin-based combination therapy (ACT) is the first-line anti-malarial treatment of uncomplicated malaria in most endemic countries, including Tanzania. Unfortunately, there have been reports artemisinin resistance and ACT failure from South East Asia highlighting need to monitor therapeutic efficacy these countries as recommended by World Health Organization.Open-label single arm studies mainland Tanzania were conducted nine sentinel sites 2011, 2012 2015 assess safety...
Abstract Background The World Health Organization recommends regular therapeutic efficacy studies (TES) to monitor the performance of first and second-line anti-malarials. In 2016, safety artemether-lumefantrine (AL) for treatment uncomplicated falciparum malaria were assessed through a TES conducted between April October 2016 at four sentinel sites Kibaha, Mkuzi, Mlimba, Ujiji in Tanzania. study also molecular markers artemisinin lumefantrine (partner drug) resistance. Methods Eligible...
High-throughput Plasmodium genomic data is increasingly useful in assessing prevalence of clinically important mutations and malaria transmission patterns. Understanding parasite diversity for identification specific human or populations that can be targeted by control programmes, to monitor the spread associated with drug resistance. An up-to-date understanding regional population dynamics also critical impact efforts. However, this largely absent from high-burden nations Africa, date, no...
Therapeutic efficacy studies (TESs) and detection of molecular markers drug resistance are recommended by the World Health Organization (WHO) to monitor artemisinin-based combination therapy (ACT). This study assessed trends artemisinin and/or reduced susceptibility lumefantrine using samples collected in TES conducted Mainland Tanzania from 2016 2021.
Abstract Background Tanzania is currently implementing therapeutic efficacy studies (TES) in areas of varying malaria transmission intensities as per the World Health Organization (WHO) recommendations. In TES, distinguishing reinfection from recrudescence critical for determination anti-malarial efficacy. Recently, WHO recommended genotyping polymorphic coding genes, merozoite surface proteins 1 and 2 (msp1 msp2) , replacing glutamate-rich protein ( glurp ) gene with one highly...
Abstract Background In 2015, a China-UK-Tanzania tripartite pilot project was implemented in southeastern Tanzania to explore new model for reducing malaria burden and possibly scaling-out the approach into other malaria-endemic countries. The 1,7-malaria Reactive Community-based Testing Response (1,7-mRCTR) which is locally-tailored reporting febrile cases endemic villages developed stop transmission Plasmodium life-cycle. utilizes existing health facility data locally trained community...
Abstract Background Artemisinin-based combination therapies (ACTs) have been a major contributor to the substantial reductions in global malaria morbidity and mortality over last decade. In Tanzania, artemether-lumefantrine (AL) was introduced as first-line treatment for uncomplicated Plasmodium falciparum 2006. The WHO recommends regular assessment monitoring of efficacy treatment, specifically considering that artemisinin resistance has confirmed Greater Mekong sub-region. This study's...
Praziquantel (PZQ) is currently the only recommended drug for infection and disease caused by schistosome species that infects humans; however, current tablet formulation not suitable pre-school age children mainly due to its bitterness large size. We assessed palatability of two new orally disintegrating (ODT) formulations PZQ.This randomized, single-blind, crossover, swill-and-spit study (NCT02315352) was carried out at a single school in Tanzania aged 6-11 years old, with or without...
Abstract Background Progress in malaria control has stalled recent years and innovative surveillance response approaches are needed to accelerate elimination efforts endemic areas of Africa. Building on a previous China-UK-Tanzania pilot study control, this aimed assess the impact 1,7-malaria Reactive Community-Based Testing Response (1,7-mRCTR) approach implemented over two three districts Tanzania. Methods The 1,7-mRCTR provides community-based testing via rapid diagnostic tests treatment...
Abstract Background Artemisinin-based combination therapy (ACT) has been a major contributor to the substantial reductions in global malaria morbidity and mortality over last decade. In Tanzania, artemether-lumefantrine (AL) was introduced as first-line treatment for uncomplicated Plasmodium falciparum 2006. The World Health Organization (WHO) recommends regular assessment monitoring of efficacy treatment, specifically considering that artemisinin resistance confirmed Greater Mekong...
The antimalarial drug piperaquine is associated with delayed ventricular depolarization, causing prolonged QT interval (time taken for de-polarisation and re-polarisation). There a lack of safety data regarding dihydroartemisinin/piperaquine (DHA/PPQ) the treatment uncomplicated malaria, which has limited its use. We created platform where electrocardiograms (ECG) were performed in public hospitals assessment DHA/PPQ, at baseline before use (Eurartesim®), on day 3 (before after...
Abstract Background The use of artemisinin-based combination therapy (ACT) is recommended by the World Health Organization for treatment uncomplicated falciparum malaria. Artemether-lumefantrine (AL) most widely adopted first-line ACT malaria in sub-Saharan Africa (SSA), including mainland Tanzania, where it was introduced December 2006. WHO recommends regular assessment to monitor efficacy specifically considering that artemisinin partial resistance reported Greater Mekong sub-region and...
Abstract Background Primaquine is a gametocytocidal drug recommended by the World Health Organization (WHO) in single-low dose combined with artemisinin-based combination therapy (ACT) for treatment and prevention of Plasmodium falciparum malaria transmission. Safety monitoring concerns lack universal validated approved primaquine pharmacovigilance tool challenge national rollout many countries. This study aimed to explore acceptance, reliability perceived effectiveness roll out (PROMPT)....
ABSTRACT High-throughput Plasmodium genomic data is increasingly useful in assessing prevalence of clinically important mutations and malaria transmission patterns. Understanding parasite diversity for identification specific human or populations that can be targeted by control programs, to monitor the spread associated with drug resistance. An up-to-date understanding regional population dynamics also critical impact efforts. However, this largely absent from high-burden nations Africa,...
Abstract Background : Use of artemisinin combination therapy (ACT) is recommended by the World Health Organization (WHO) for treatment uncomplicated falciparum malaria. Artemether-lumefantrine (AL) most widely adopted first-line ACT malaria in sub-Saharan Africa (SSA), including mainland Tanzania, where it was introduced December 2006. The WHO recommends regular assessment to monitor efficacy specifically considering that partial resistance reported Greater Mekong sub-region and has been...
Abstract Background Therapeutic efficacy studies (TESs) and detection of molecular markers drug resistance are recommended by the World Health Organization (WHO) to monitor artemis inin combination therapy (ACT). This study assessed trends and/or reduced susceptibility lumefantrine using samples collected in TES conducted Mainland Tanzania from 2016 2021. Methods A total 2,015 were during artemether-lumefantrine at eight sentinel sites (in Kigoma, Mbeya, Morogoro, Mtwara, Mwanza, Pwani,...
Artemether-lumefantrine (AL) is the first line anti-malarial drug for treatment of uncomplicated malaria in Tanzania. The World Health Organization (WHO) recommends regular efficacy monitoring drugs to inform case management policy decisions. This study assessed safety and AL treating P. falciparum Tanzania 2022.
Abstract A pilot implementation of the rapid diagnostic test program was performed to collect evidence feasibility, acceptability, and uptake COVID-19 AgRDT in Tanzania. We conducted a prospective cross-sectional study community provide quantitative details antigen (AgRDT) This undertaken between March 2022 September 2022. The implemented by distributing offering kits people suspected having Dar es Salaam through health workers. total 1039 participants consented participate survey. All...
<title>Abstract</title> Background: Reactive case detection (RACD) for malaria control has been found effective in low transmission settings, but its impact and cost-effectiveness moderate-high settings are unknown. We conducted an economic evaluation alongside empirical trial of a modified RACD strategy (1,7-mRCTR) three high districts Tanzania. Methods: The costs cost-savings associated with the intervention to passive alone were estimated, simulation model was utilized assess terms...
The rapid diagnosis of coronavirus disease 2019 (COVID-19) is critical for comprehensive public health response strategies, and self-testing with antigen diagnostic tests (Ag-RDTs) presents opportunities to test in hard-to-reach communities. Therefore, we evaluated the acceptability, feasibility, uptake Ag-RDT at community level Tanzania. From June October 2022, symptomatic individuals or those recent contact a known suspected COVID-19 patient were offered assisted testing within mining...
Abstract Background Reactive case detection (RACD) for malaria control has been found effective in low transmission settings, but its impact and cost-effectiveness moderate-to-high settings are unknown. We conducted an economic evaluation alongside empirical trial of a modified RACD strategy (1,7-mRCTR) three districts Tanzania. Methods The costs cost savings associated with the intervention relative to passive alone were estimated study sites Kilwa, Kibiti, Rufiji Tanzania from 2019–2021....
Abstract Background Praziquantel (PZQ) is currently the only recommended drug for infection and disease caused by species of schistosome infecting humans; however, current tablet formulation not suitable preschool age children mainly due to its bitterness size tablet. We assessed palatability two new orally disintegrating (ODT) formulations PZQ. Methods This randomized, single-blind, crossover, swill-and-spit study ( NCT02315352 ) was carried out at a single school in Tanzania aged 6–11...
Abstract Background: In 2015, a China-UK-Tanzania tripartite pilot project was implemented in south-eastern Tanzania to explore new model for reducing malaria burden and possibly scaling-out the approach into other endemic countries. The 1,7-malaria Reactive Community-based Testing Response (1,7-RCTR) which is locally-tailored reporting febrile cases villages developed stop transmission plasmodium life-cycle. utilizes existing health facility data locally trained community workers conduct...
Abstract Background Tanzania is currently implementing therapeutic efficacy studies (TES) in areas of varying malaria transmission intensities as per the World Health Organization’s (WHO) recommendations. In TES, distinguishing reinfection from recrudescence critical for determination antimalarial efficacy. Recently, WHO recommended genotyping polymorphic coding genes ( msp1, msp2 , and glurp ) highly neutral microsatellites Plasmodium falciparum to adjust antimalarials TES. This study...
Background: In 2015, a China-UK-Tanzania tripartite pilot project was implemented in south-eastern Tanzania to explore new model reduce the malaria burden with aim of eventually scaling-up approach Africa. Chinese and Tanzanian teams have developed locally-tailored control screening for febrile cases endemic villages on Day 1 followed by focal treatment holoendemic within 7 days stop transmission at same phase plasmodium life-cycle. This 1,7-Reactive Community-based Testing Response...